Evidence that aberrant protein metabolism contributes to chemoresistance in multiple myeloma cells

Multiple myeloma (MM) is an incurable B lymphocyte cancer. To date, a comparative analysis of global protein metabolism for the MM cell line CCL-155 (RPMI-8226) and the non-cancerous B lymphocyte cell line CCL-156 (RPMI‑1788) has not been published. Here, we report that both global protein synthesis...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Oncology reports 2012-06, Vol.27 (6), p.2031-2038
Hauptverfasser:	SIPES, Richard K, XUE XIA, LEWIS, Brian S, BURGIS, Nicholas E
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - pharmacology B-Lymphocytes - metabolism Biological and medical sciences Cell Line, Tumor Cell Proliferation - drug effects Chloroquine - pharmacology Drug Resistance, Neoplasm Humans Immunodeficiencies. Immunoglobulinopathies Immunoglobulinopathies Immunopathology Leupeptins - pharmacology Lysosomes - drug effects Lysosomes - metabolism Male Medical sciences Melphalan - pharmacology Multiple Myeloma - drug therapy Multiple Myeloma - metabolism Neoplasm Proteins - metabolism Proteasome Endopeptidase Complex - metabolism Proteins - metabolism Proteolysis - drug effects Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!